RxDoctor Payments Data

Abdulrahman Abutaleb, MD

Interventional Cardiology · Barrington, ILNPI 1891185609

Payments from drug & device makers

$6,880in general payments, 2019–2025

Across 117 payments — averaging $58.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Abbott$1K
  • Medtronic$1K
  • ZOLL Circulation Inc$984
  • Boston Scientific$381
  • W. L. Gore & Associates, Inc.$152
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$3,36249%
  • Food & beverage$3,23347%
  • Education$2854%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,880 in reported general payments places this provider in the 40th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$269,875
Medicare patients
1,813
Services billed
4,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$89,499
JardianceEmpagliflozin48$62,871
EntrestoSacubitril/Valsartan27$26,131
XareltoRivaroxaban20$18,983
Repatha SureclickEvolocumab14$9,897
BrilintaTicagrelor15$8,679
Metoprolol Succinate189$2,754
Rosuvastatin Calcium175$2,709
Atorvastatin Calcium102$1,131
ClopidogrelClopidogrel Bisulfate89$1,087
Prasugrel Hcl13$992
Carvedilol138$956
Ezetimibe30$635
Losartan Potassium71$582
Nifedipine ErNifedipine14$575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$89,49995 claims
NovartisEntresto$115$26,13127 claims
Johnson & JohnsonXarelto$141$18,98320 claims
AstraZenecaBrilinta$59$8,67915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Barrington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →